Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer, today announced that it received notice of a $750,000 grant from the Alzheimer’s Association under the 2020 Part the Cloud Program to evaluate its lead drug candidate, pepinemab (VX15), in Alzheimer’s Disease (AD). Eric Siemers, MD, formerly senior medical director of the Alzheimer's Disease Global Development Program at Eli Lilly and Company, will serve as Senior Medical Director of this 60 subject, randomized, placebo-controlled, multi-center clinical study which is expected to start enrolling in 2Q 2020.
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim data of the Phase 1b/2 study of pepinemab in combination with anti-PD-L1 checkpoint inhibitor, BAVENCIO® (avelumab), in non-small cell lung cancer (NSCLC) is being reported during a poster presentation on Saturday, November 9 at the 34th Annual Meeting of The Society for Immunotherapy of Cancer (“SITC”). Below is a summary of updated interim data from the poster presentation.
Vaccinex Inc (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and nuerodegenerative diseases, today announced that it presented the scientific rationale and design of its recently announced Phase 1 study of pepinemab (VX15/2503) for Alzheimer’s Disease (AD) in a podium presentation on Saturday, December 7 at the 12th Clinical Trials on Alzheimer's Disease Conference in San Diego, USA. The CTAD Conference is a premier annual Alzheimer’s Disease event.
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and neurodegenerative diseases, today announced that the company has entered into two agreements that combined could provide a total of up to $16.5 million in equity financing. On March 27, 2020, Vaccinex put in place an open sale market agreement (an “At the Market” agreement, or ATM) pursuant to which it can issue and sell shares of its common stock from time to time for an aggregate sales price of up to $11.5 million. The common stock to be sold under the ATM agreement, if any, will be issued and sold pursuant to the company’s S-3 shelf registration statement previously filed with the Securities and Exchange Commission and declared effective on March 11, 2020.
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today announced the presentation of updated interim results from CLASSICAL-Lung, the Company’s Phase 1b/2 study of pepinemab in combination with anti-PD-L1 checkpoint inhibitor avelumab (BAVENCIO®) in non-small cell lung cancer (NSCLC), at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, being held April 27-28, 2020. The data will be presented in a virtual poster session, available on demand and free to anyone on the AACR website beginning April 27.
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer, today announced that it has been granted an award, in the form of an investment of up to approximately $3 million, from the Alzheimer’s Drug Discovery Foundation (ADDF) to evaluate its lead drug candidate, pepinemab (VX15/2503), in Alzheimer’s Disease (AD). The mission of the ADDF is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease.
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced financial results for the fourth quarter ended December 31, 2019 and provided a corporate update. Expansion of the pepinemab development program to include Alzheimer’s disease based on findings from Cohort A of the company’s ongoing SIGNAL Huntington’s disease study was announced.
Vaccinex Inc (VCNX) delivered earnings and revenue surprises of 8.16% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update. Presented updated interim data from the CLASSICAL-Lung Phase 1b/2 study of the company’s lead product candidate, pepinemab, in combination with avelumab (BAVENCIO®) in non-small cell lung cancer (NSCLC) at the American Association for Cancer Research Virtual Annual Meeting.
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced financial results for the third quarter ended September 30, 2019 and provided a corporate update.
ROCHESTER, N.Y., Feb. 06, 2020 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and.
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced a poster presentation highlighting interim results from CLASSICAL-Lung, the Company’s Phase 1b/2 study of pepinemab in combination with the anti-PD-L1 checkpoint inhibitor BAVENCIO® (avelumab) in non-small cell lung cancer (NSCLC), at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, being held virtually May 29-31, 2020. “We are pleased to announce that updated data from the CLASSICAL-Lung trial of combination treatment with pepinemab and avelumab confirms earlier signs of anti-tumor activity, most notably in patients for whom previous treatment with anti–PD-1/PD-L1 therapies failed and those who have PD-L1–negative or –low tumors,” said Dr. Maurice Zauderer, President and CEO of Vaccinex.
NEW YORK, Sept. 06, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Vaccinex, Inc. (NASDAQCM: VCNX) concerning possible breaches of fiduciary duty..
ROCHESTER, N.Y., Sept. 24, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and.
ROCHESTER, N.Y., Sept. 27, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and.
GERMANTOWN, Md., Oct. 31, 2019 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and neurodegenerative diseases, today announced that the company’s vice president of preclinical research, Elizabeth Evans, Ph.D, delivered a virtual presentation at the Alzheimer’s and Parkinson’s Therapies AAT-AD/PD™ Focus Meeting 2020, which was held from April 2-5. The presentation, entitled, “Regulation of Glial Cell Activation and Neurodegeneration by Anti-Semaphorin 4D Antibody Pepinemab, Potential Treatment for Alzheimer’s and Huntington’s Disease,” summarizes compelling findings from 19 patients enrolled in the company’s ongoing SIGNAL Phase 2 trial of pepinemab for the treatment of Huntington’s disease.